Biologics as Savior:

Biologics or biopharmaceuticals are pioneers of developments in the biotechnology segment. These are synthesized from various biological sources as opposed to synthetic drugs. Biologics are made up of living cells, gene components, sugars, proteins, nucleic acids, tissues, allergenic, and also vaccines. These components are isolated from live sources and composed using recombinant DNA (rDNA) technology to cure the diseases with minimal side effects. Biologics have become a savior for many patients by aiding the medical practitioners in treating a variety of illnesses and conditions which have no other treatments available currently.

Advantages and Disadvantages of Biologics:

Many patients suffering from diseases such as chronic inflammation found relief by adopting biologics. It has helped them by reducing their dependency on health and welfare systems and improve their biological and physical functions to live independently. With the evolution of biologics, biosimilars have also entered this domain to make these effective therapies more affordable for the common population, although, concerns are being raised by industry experts regarding the after effects of biosimilars, which might add to the concerns of safety and after effects of the therapies.

Market Scenario for Biologics:

In 2016, the global biologics market registered a revenue of $238.8 million, which has been a result of widespread adoption of therapies. The future demand for biologics is expected to be fuelled by the introduction of targeted therapies and the rising adoption of patient centric personalized medicine. The development of novel therapeutic biologic drugs, owing to the vast research in the understanding of the cell physiology and stress, as well as the factors involved in protein production and heterologous gene expression, which have empowered the use of different living factories, has also propelled the market towards growth.

The emerging economies are witnessing a robust growth with regards to biologics, along with the increasing adoption of monoclonal antibodies (MAbs) and human insulin for the treatment of patients. In addition to this growth, the step to introduce biosimilar pathways by some of the governments (including the U.S. and Europe) to further the competition in the market is driving the growth of the market. In 2016, MABs maintained their ranking as the highest selling class of biologics, with their U.S. sales reaching approx. $37.6 billion, an 18.3% growth over their 2015 sales, which vaulted Roche, with 11 monoclonal in the market, to the top spot among companies with biologic products. The growth of the MABs sector was driven by a high growth in the sales of both MAbs for oncology and anti-inflammatory disorders.

A Ray of Hope for Cancer Treatment:

Many of the products in the biologics pipeline are devoted to oncology and related diseases. The high incidence rate of 70% over next two decades and the current pressure over the society makes cancer a critical issue to be dealt with urgently and strict measures to reduce the number of prevalent cases. In 2016, the biologics market was valued at $238 billion, predominantly represented by monoclonal antibodies. The biologics market for cancer is anticipated to reach $155 billion by 2025.

BIS Healthcare has conducted an extensive market research on ‘Global Biologics Market -Analysis and Forecast (2017-2025)‘. The market intelligence report aims to provide an in-depth analysis of the key development strategies, marketing strategies and market trend dynamics which include drivers, restraints, and opportunities prevailing in the industry.

For further queries, please write to us at sales@bisresearch.com or call us at +1 650 228 0182.